



1645

Docket No. 1758-4036US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): MINETTI, C, et al.

Group Art Unit: 1645

RECEIVED

Serial No.: 09/120,044

Examiner: S. Devi

JUL 17 2001

Filed: July 21, 1998

TECH CENTER 1600/2900

For: MODIFIED IMMUNOGENIC PNEUMOLYSIN COMPOSITIONS AS VACCINES

CERTIFICATE OF MAILING (37 C.F.R. §1.8(a))Commissioner for Patents
Washington, D.C. 20231

Sir:

I hereby certify that the attached:

1. Amendment and Response to Official Action (14 pages); and
2. Return Postcard.

along with any paper(s) referred to as being attached or enclosed and this Certificate of Mailing are being deposited with the United States Postal Service on date shown below with sufficient postage as first-class mail in an envelope addressed to the: Commissioner for Patents, Washington, D.C., 20231.

Respectfully submitted,
MORGAN & FINNEGAN, L.L.P.Dated: July 9, 2001By: Darryl H. Steensma
Darryl H. Steensma
Registration No. 43,155Correspondence Address:MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



RECEIVED

JUL 17 2001

TECH CENTER 1600/2900

PATENT
DOCKET NO. 1758-4036US2

Handwritten: #29/6
7/18/01
Not

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : MINETTI, C. et al. Art Unit : 1645
Serial No : 09/120,044 Examiner : S. Devi
Filed : July 21, 1998
For: : MODIFIED IMMUNOGENIC PNEUMOLYSIN
COMPOSITIONS AS VACCINES

AMENDMENT AND RESPONSE TO OFFICIAL ACTION

COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Sir:

In response to the Official Action mailed April 10, 2001, applicants present the following amendment and remarks. Claims 1-15, 27-26, and 31-34 are pending in the application. Applicants herewith cancel the pending claims and add new claims 35-64.

AMENDMENT

Please ~~cancel~~ claims 1-15, 22-26, and 31-34.

Please ~~add~~ the following claims.

- Sub P1*
25
35. A pneumolysin polypeptide comprising SEQ ID NO: 3, wherein the polypeptide is modified, refolded and has attenuated hemolytic activity, and wherein the polypeptide has at least one amino acid substitution in the region comprising amino acids 1 to 257.